129 related articles for article (PubMed ID: 37585199)
41. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
[TBL] [Abstract][Full Text] [Related]
42. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
43. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
[TBL] [Abstract][Full Text] [Related]
45. Characteristics of Familial Melanoma in Valencia, Spain, Based on the Presence of CDKN2A Mutations and MC1R Variants.
Huerta C; Garcia-Casado Z; Bañuls J; Moragon M; Oliver V; Unamuno B; Requena C; Kumar R; Nagore E
Acta Derm Venereol; 2018 Apr; 98(5):512-516. PubMed ID: 29405243
[TBL] [Abstract][Full Text] [Related]
46. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
[TBL] [Abstract][Full Text] [Related]
47. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
Randerson-Moor JA; Harland M; Williams S; Cuthbert-Heavens D; Sheridan E; Aveyard J; Sibley K; Whitaker L; Knowles M; Bishop JN; Bishop DT
Hum Mol Genet; 2001 Jan; 10(1):55-62. PubMed ID: 11136714
[TBL] [Abstract][Full Text] [Related]
48. Association Between Confocal Morphologic Classification and Clinical Phenotypes of Multiple Primary and Familial Melanomas.
Grazziotin TC; Alarcon I; Bonamigo RR; Carrera C; Potrony M; Aguilera P; Puig-Butillé JA; Brito J; Badenas C; Alós L; Malvehy J; Puig S
JAMA Dermatol; 2016 Oct; 152(10):1099-1105. PubMed ID: 27579522
[TBL] [Abstract][Full Text] [Related]
49. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
50. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
51. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
Marker DF; Pearce TM
Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
[TBL] [Abstract][Full Text] [Related]
52. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
[TBL] [Abstract][Full Text] [Related]
53. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
54. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.
van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W
J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156
[TBL] [Abstract][Full Text] [Related]
55. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
[TBL] [Abstract][Full Text] [Related]
56. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
58. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
[TBL] [Abstract][Full Text] [Related]
59. Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants.
Li C; Liu T; Tavtigian SV; Boucher K; Kohlmann W; Cannon-Albright L; Grossman D
Melanoma Res; 2020 Jun; 30(3):247-251. PubMed ID: 31567591
[TBL] [Abstract][Full Text] [Related]
60. Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants.
Agaimy A; Märkl B; Kitz J; Wünsch PH; Arnholdt H; Füzesi L; Hartmann A; Chetty R
Virchows Arch; 2010 Apr; 456(4):411-22. PubMed ID: 20155280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
